SAU:4016

Middle East Pharmaceutical Industries Company · SAU · Healthcare · SAR · FY for 2025

Figures on this page computed 2026-11-08 12:42 UTC

Last close

n/aSAR

Market data

23.4xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
SAR
- computed
- Computed from the filing for 2025
22.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
21.1%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
17.0%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
0.15Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
SAR
- computed

What it pays out is the furthest below its sector's middle: 0.35 against 0.54 on the market's range.

Five bars, one line

lens 7 of 9

1.39x

1.37x

1.95x

1.02x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales1.39x
Its own average over 7 years, 330.9M.
Profit1.37x
Its own average over 7 years, 70.8M.
Free cash flow1.95x
Its own average over 7 years, 40.3M.
Debt1.02x
Its own average over 7 years, 62.3M.
Pricen/a
Its own average over 0 years. Market data

Free cash flow is furthest from its own average, at 1.95 times.

Sales is 1.39 times its own 7-year average; Profit is 1.37 times its own 7-year average; Free cash flow is 1.95 times its own 7-year average; Debt is 1.02 times its own 7-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 7-year average1.39
Source
computed
Statement
income
Fiscal year
2025
Reported in
SAR
Profit against its own 7-year average1.37
Source
computed
Statement
income
Fiscal year
2025
Reported in
SAR
Free cash flow against its own 7-year average1.95
Source
computed
Statement
income
Fiscal year
2025
Reported in
SAR
Debt against its own 7-year average1.02
Source
computed
Statement
income
Fiscal year
2025
Reported in
SAR
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
SAR